Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients

Sponsor
Assiut University
Study ID
NCT07003451
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Calprotectin Level — DIAGNOSTIC_TEST
    Measurement of calprotectin level to presence and severity of ILD asessed via Warrick's score

Study Details

\- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients

Key Dates

First listed
Jun 4, 2025
Start date
Oct 1, 2025
Status verified
Aug 2025
Primary completion
Jan 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Rheumatoid Arthritis with ILD
    Rheumatoid arthritis patients with interstitial lung disease diagnosed by high resolution CT and correlated to level of biomarkers

Primary Outcome Measure

calprotectin level among rheumatoid arthritis patients with interstitial lung disease [ Time Frame: day 1 ]

Central Contacts

Find similar trials

Nationwide
Rheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies